🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

EDSA EDSA

Company Profile ↓
$5.17
+127.75% 1Y
P/E-9.07
52W High$18.28
52W Low$0.80
EPS (TTM)$-0.57

Company Overview

EDSA (EDSA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.00.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -100.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-
1 Year:-100.00%

Stock Price Performance

1 Year:+127.75%
6 Months:+353.51%
3 Months:-66.56%
1 Month:-29.18%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 25% of range
$0.80 $18.28
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)36.98 · Neutral
Price Performance
1M-29.18%
3M-66.56%
6M+353.51%
1Y+127.75%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 71.7% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-9.07
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-100.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-63.54%
ROE
-57.71%
ROA
-53.11%
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.14
EPS (TTM)
$-0.57

Balance Sheet & Liquidity

Debt/Equity
0.00
Quick Ratio
-
Current Ratio
4.76
Debt
-
Total Assets
$12.38M
Current Assets
$10.42M
Working Capital
$8.23M

Ownership

Promoter Holding
18.66%
Chg in Prom Hold
-
FII / Inst Holding
38.71%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$0
EBITDA
-
Free Cash Flow
$-7.32M
Operating Cash Flow
$-7.32M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2013Mar 2014Jun 2014Dec 2014Mar 2015Jun 2015Dec 2015Mar 2016Jun 2016Dec 2016Mar 2017Jun 2017Dec 2017Mar 2018Jun 2018Dec 2018Mar 2019Jun 2019Dec 2019Mar 2020Jun 2020Dec 2020Mar 2021Jun 2021Dec 2021Mar 2022Jun 2022Dec 2022Mar 2023Jun 2023Dec 2023Mar 2024Jun 2024Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue 58.83K114.37K72.54K212.66K187.63K157.75K488.16K326.33K181.09K141.86K63.02K20.53K20.49K64.05K000500107.80K110.52K109.98K000--------------
Operating Income -------1.31M-1.10M-1.19M-1.41M-1.15M-1.29M-1.39M-1.34M-421.99K-405.74K-540.78K-1.32M-1.11M-1.52M-1.77M-2.61M-9.51M-6.07M-5.16M-4.58M-5.80M-2.38M-2.41M-2.06M-1.86M-2.22M-1.93M-1.90M-1.64M-1.90M-2.34M-4.30M
Net Income -5.58M-1.43M3.41M-1.34M-426.16K463.99K-1.63M-861.01K-1.19M-1.49M-1.10M-1.22M-1.40M-1.35M-411.84K-364.85K-528.83K-1.29M-1.09M-1.49M-1.77M-2.64M-2.26M-4.76M-4.38M-4.57M-5.79M-2.33M-2.33M-1.98M-1.68M-1.86M-1.67M-1.62M-1.59M-1.75M-2.25M-4.22M
Diluted EPS -0.08-0.020.04-0.02-0.010.05---0.14-----------------------------
R&D Expense 548.23K733.10K543.23K418.82K281.58K129.71K288.85K309.06K470.10K460.87K329.37K536.17K631.03K493.87K298.22K257.39K111.70K502.93K528.00K502.81K1.14M1.38M7.98M4.46M3.95M3.04M4.55M1.36M1.46M1.03M704.46K1.18M897.30K1.02M484.31K939.07K1.12M2.77M

Profit & Loss (Annual)

Figures in USD.

Metric Aug 2012Aug 2013Aug 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Revenue 286.05K545.47K372.13K758.69K1.27M228.29K211.85K328.80K0----
Operating Income ---5.72M-4.34M-4.91M-5.22M-5.08M-6.40M-23.68M-18.37M-9.22M-7.01M-7.91M
Net Income -5.53M-14.50M-8.44M-2.84M-5.03M-5.03M-5.04M-6.36M-13.34M-17.55M-8.37M-6.17M-7.19M
Diluted EPS --2.81-1.11-0.36-0.57--------
R&D Expense 2.63M2.02M2.46M1.03M1.73M1.97M2.09M3.33M17.95M13.34M4.79M2.88M3.67M

Balance Sheet (Annual)

Figures in USD.

Metric Aug 2011Aug 2012Aug 2013Aug 2014Sep 2014Sep 2015Sep 2016Sep 2017Sep 2018Dec 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Total Assets --8.51M14.47M14.83M10.39M12.94M7.72M11.78M-5.72M10.76M14.58M11.58M8.89M3.81M13.53M
Total Equity 3.44M902.16K-2.20M7.70M10.46M8.01M12.31M7.40M11.29M3.21M5.26M6.63M13.06M9.39M7.05M1.98M12.45M
Cash & Equivalents 4.15M999.00K7.86M8.42M8.77M3.96M7.42M4.57M4.23M3.37M5.03M7.21M7.84M7.09M5.40M1.00M10.80M
Total Liabilities --10.71M6.77M4.36M2.38M----461.63K1.65M1.53M2.18M1.84M1.83M-
Current Liabilities --3.87M1.42M672.17K2.38M623.64K320.95K493.38K-461.63K1.53M1.46M2.14M1.82M1.83M1.08M

Cash Flows (Annual)

Figures in USD.

Metric Aug 2012Aug 2013Aug 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Operating Cash Flow ----4.41M-4.51M-4.70M-4.62M-4.99M--12.28M-6.64M-4.89M-7.32M
Investing Cash Flow ---122.47K557.41K1.69M-4.47M19.07K-6.15K-5.66K0--
Financing Cash Flow ---106.78K7.31M08.77M7.09M-11.63M4.83M592.03K17.03M
Capital Expenditure -78.34K-9.54K-279.06K-274.59K-402.27K-302.73K-382.81K-4.86K-6.15K-5.66K---
Free Cash Flow ----4.69M-4.91M-5.00M-5.00M-4.99M--12.28M-6.64M-4.89M-7.32M
Net Change in Cash ----------655.33K-1.81M-4.30M9.71M

Ratios (Annual)

Figures in %.

Metric Aug 2012Aug 2013Aug 2014Sep 2015Sep 2016Sep 2017Sep 2018Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Gross Margin % -------------
Operating Margin % ---1,536.7%-571.9%-386.0%-2,288.6%-2,397.1%-1,946.7%-----
Net Margin % -1,932.9%-2,657.5%-2,267.9%-374.7%-395.2%-2,203.7%-2,378.6%-1,935.3%-----
ROE % -612.9%660.1%-109.6%-35.5%-40.8%-68.0%-44.6%-96.0%-102.2%-186.9%-118.8%-311.4%-57.7%
ROCE % ---43.8%-54.2%-39.9%-70.6%-45.0%-69.3%-180.4%-194.7%-130.5%-354.1%-63.5%

Shareholding Pattern

Insiders
18.66%
Institutions
38.71%
Public Float
47.60%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for EDSA

Yahoo Finance hu, 02 Jul 2026

EDSA: Positive Exploratory Data in Patients with AKI

By David Bautz, PhD NASDAQ: EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Positive Exploratory Data for Paridiprubart in AKI In June 2026, Edesa Biotech, Inc. (NASDAQ: EDSA) announced the presentation of positive exploratory data …

Yahoo Finance hu, 11 Jun 2026

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today an…

Yahoo Finance Fri, 05 Jun 2026

Sector Update: Healthcare Stocks Gain Friday Afternoon

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index increasing 1.2% and the Stat

Yahoo Finance Fri, 05 Jun 2026

Top Midday Stories: Lululemon Down After Fiscal Q1 Results; Amazon Engineers Criticize AI Spending; Hoffman to Exit Microsoft Board

All three major US stock indexes were down late Friday morning following a better-than-expected May

Yahoo Finance Fri, 05 Jun 2026

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

Analyses demonstrate consistent positive signals across endpoints in AKI patientsFindings derived from post hoc analysis of 101 patients also experiencing respiratory distressNew data and analysis to be presented today at the 63rd European …

Yahoo Finance Fri, 22 May 2026

EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Vitiligo Trial to Initiate in Mid-2026 Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of EB06, its anti-CXCL10 monoclonal antibody, for th…

EDSA — Frequently Asked Questions

What is the current share price of EDSA?

As of 2026-08-05 17:25 PDT, EDSA trades at $5.17 on NASDAQ/NYSE. Its 52-week range is $0.80 to $18.28.

What is the P/E ratio of EDSA?

EDSA trades at a trailing price-to-earnings (P/E) ratio of -9.07.

What is the return on equity (ROE) of EDSA?

EDSA has a return on equity (ROE) of -57.71%. Its return on capital employed (ROCE) is -63.54%.

Is EDSA a good stock to buy?

This page provides a data-driven analysis of EDSA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space